AltraVax

Altravax was incorporated in 2009 and is a privately held biopharmaceutical company based in North Dakota with research facilities in Sunnyvale, California. The Company is focused on the discovery and development of novel products to fight infectious diseases and other conditions. Our proprietary Immunogen Optimization System™ (IOS) offers unique opportunities to create novel vaccines or improve currently available alternatives to fill unmet medical needs. The Company has a robust pipeline of candidates at various stages of development, including a therapeutic vaccine against chronic hepatitis B infection and a preventive vaccine against all four dengue virus. Altravax seeks strategic alliances to develop these lead candidates for clinical testing.

AltraVax headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Biopharma sector. The company focuses on Biotechnology and has secured $48.2M in funding across 24 round(s). With a team of 11-50 employees, AltraVax is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - AltraVax, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.